Sevoflurane

Generic Name
Sevoflurane
Brand Names
Sevorane, Sojourn, Ultane
Drug Type
Small Molecule
Chemical Formula
C4H3F7O
CAS Number
28523-86-6
Unique Ingredient Identifier
38LVP0K73A
Background

Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than desflurane, but has lower potency compared to halothane and isoflurane. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.

Indication

Sevoflurane is used for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia

Optimal Sevoflurane Concentration for Intubation in Combination of Clincal Remifentanil Doses

First Posted Date
2015-05-12
Last Posted Date
2019-01-17
Lead Sponsor
Severance Hospital
Target Recruit Count
68
Registration Number
NCT02440204
Locations
🇰🇷

Armed Forces Capital Hospital, Republic of Korea, Seongnam-si, Kyung-ki Do, Korea, Republic of

Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor

Not Applicable
Conditions
Interventions
First Posted Date
2015-04-29
Last Posted Date
2017-01-24
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
30
Registration Number
NCT02428972

Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-04-29
Last Posted Date
2015-04-29
Lead Sponsor
University of Sulaimani
Target Recruit Count
100
Registration Number
NCT02429323

Scalp Nerve Block on Emergence Agitation

First Posted Date
2015-04-28
Last Posted Date
2017-01-25
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
44
Registration Number
NCT02428283
Locations
🇰🇷

Ajou University Hospital, Suwon, Gyeongki-do, Korea, Republic of

Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia

First Posted Date
2015-04-17
Last Posted Date
2019-10-09
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
11
Registration Number
NCT02419547
Locations
🇺🇸

Brigahm and Women's Hospital, Boston, Massachusetts, United States

Anesthetics in Rhytidoplasty - A Comparison Study

First Posted Date
2015-04-07
Last Posted Date
2015-04-07
Lead Sponsor
Mercy Facial Plastic Surgery Center
Target Recruit Count
30
Registration Number
NCT02410460
Locations
🇺🇸

Mercy Facial Plastic Surgery Center, Springfield, Missouri, United States

Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2015-04-03
Last Posted Date
2018-03-09
Lead Sponsor
Triemli Hospital
Target Recruit Count
2
Registration Number
NCT02407626
Locations
🇨🇭

Triemli City Hospital, Zurich, Switzerland

Myocardial Protection and Anesthetic Agents

First Posted Date
2015-04-01
Last Posted Date
2015-12-10
Lead Sponsor
Cukurova University
Target Recruit Count
60
Registration Number
NCT02405689
Locations
🇹🇷

Cukurova University, Adana, Turkey

© Copyright 2024. All Rights Reserved by MedPath